Heart Failure – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis – Heart Failure – Reduced Ejection Fraction (US)
Drug treatment of chronic heart failure with reduced ejection fraction (HFrEF) is well established, with a wealth of supporting evidence from clinical trials. ACE inhibitors or ARBs, beta blockers, and loop diuretics are typically used in the first-line treatment of HFrEF patients. Given the heavily genericized nature of the market, branded agents, such as Novartis’s Entresto, Amgen’s Corlanor, AstraZeneca’s Farxiga, and Eli Lilly’s Jardiance, have had difficulty establishing a foothold; nevertheless, use of Entresto has grown steadily since its launch in 2015. This analysis offers insight into the U.S. prescribing patterns in the HFrEF subpopulation.
Questions answered
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed HFrEF patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed HFrEF patients?
- How have Entresto, Farxiga, Jardiance, and Verquvo been integrated into the treatment algorithm, and what is their source of business?
- What percentage of HFrEF patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of HFrEF patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
Product dscription
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Markets covered: United States
Key companies: Pfizer, Merck, Novartis, GSK, AstraZeneca, Johnson & Johnson, Eli Lilly, Boehringer Ingelheim, Amgen
Key drugs: ACE inhibitors, ARBs, beta blockers, diuretics, aldosterone antagonists, nitrates, Entresto, Corlanor, Farxiga, Jardiance, Verquvo
Solution enhancement
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and optional quarterly data refreshes.
Table of contents
- Heart Failure - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis - Heart Failure - Reduced Ejection Fraction (US)
- Treatment Algorithms CDA Heart Failure Reduced Ejection Fraction US May 2023
- Treatment Algorithms CDA HFrEF 2023 Dashboard
Anuhya V., M.Pharm., is a research associate on the Cardiovascular, Metabolic, Renal, and Hematological Disorders team at Clarivate. She conducts extensive secondary market research for a variety of CMRH indications, including pulmonary hypertension (PH), nonalcoholic steatohepatitis (NASH), heart failure (including HFrEF & HFpEF). She holds a M.Pharm. degree in general pharmacy from BITS Pilani in India and a bachelor’s degree in pharmacy from G. Pulla Reddy College of Pharmacy, which is affiliated with Osmania University, in Hyderabad, India.